Shares in 23andMe are currently trading at around $3.40, giving it a valuation of just under $82 million. The company went ...
Novo Nordisk's GLP-1 agonist Ozempic has become the first drug in the class to be approved by the FDA to reduce the risk of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback